top of page
Medical Checkup

WISPer

Trial Enrolment Status

OPEN

Disease Under Study

Idiopathic Pulmonary Fibrosis

Duration

26 Weeks

About the Trial

A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Mechanism of Action:

MTX-463 is an IgG1 monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1)

Duration of Study

26 Weeks

Phase

2

Principal Investigator

Dr. George Philteos

Sub-Investigator

Dr. Anushya Chelvanathan

Study Coordinator

Asvini Kulasingham, RRT

Durham Institute of Respirology | Dynamic Drug Advancement Ltd

Address:

Hours:

601 Harwood Avenue South, Suite 201

Ajax, Ontario L1S 2J5

M-F:

9:00am - 5:00pm

Closed on statutory holidays

Main Office Phone: 

 

 

Main Office Fax:   

Clinical Trial Phone:

Clinical Trial Fax: 

Dr. Philteos: (905) 427-1419

Dr. Chelvanathan: (905) 239 0225

Dr. O'Loghlen: (905) 239 0221

(905) 427-0346

(365) 885-9086

(905) 239-0056

©2022 by Dynamic Drug Advancement. Proudly created with Wix.com

bottom of page